Osteoprotegerin and breast cancer risk by hormone receptor subtype
Renée T Fortner,
Danja Sarink,
Helena Schock,
Theron Johnson,
Anne Tjønneland,
Anja Olsen,
Kim Overvad,
Aurélie Affret,
Mathilde His,
Marie-Christine Boutron-Ruault,
Heiner Boeing,
Antonia Trichopoulou,
Androniki Naska,
Philippos Orfanos,
Domenico Palli,
Sabina Sieri,
Amalia Mattiello,
Rosario Tumino,
Fulvio Ricceri,
H Bas Bueno-De-Mesquita,
Petra Hm Peeters,
Carla H van Gils,
Elisabete Weiderpass,
Eiliv Lund,
J Ramón Quirós,
Antonio Agudo,
Maria-José Sánchez,
María-Dolores Chirlaque,
Eva Ardanaz,
Miren Dorronsoro,
Tim Key,
Kay-Tee Khaw,
Sabina Rinaldi,
Laure Dossus,
Marc Gunter,
Melissa A Merritt,
Elio Riboli,
Rudolf Kaaks
Feb 08, 2017
BACKGROUND: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and...